Poland Cancer Immunotherapy Market Analysis
Poland's cancer immunotherapy market is expected to witness growth from $653 Mn in 2022 to $1,168 Mn in 2030 with a CAGR of 7.5% for the forecasted year 2022-30. The rising prevalence of cancer and recent advancements in the research and development of immunotherapies in Poland are driving the growth of the market. The Poland cancer immunotherapy market is segmented by type, application, and end user. Mabion, Captor Therapeutics, and Bristol-Myers Squibb are the major players in the Poland cancer immunotherapy market.
Buy Now
Poland Cancer Immunotherapy Market Executive Analysis
Poland's cancer immunotherapy market is expected to witness growth from $653 Mn in 2022 to $1,168 Mn in 2030 with a CAGR of 7.5% for the forecasted year 2022-30. With budget revenues of Poland at $145 Bn and spending at $161 Bn, the draft estimates that the deficit for the following year will be $16 Bn. When the governing Law and Justice party took office in 2015, healthcare spending stood at PLN 77 Bn, but by 2018, it had increased to $38 Bn–$40 Bn. This indicates that the amount spent on health care has nearly doubled.
In Poland, where there are 38,518,241 people, cancer accounts for 25% of fatalities from all causes.1 In 2015, 12 new incident cases and 9 fatalities each day, 300 Polish citizens per day were given cancer diagnoses, and 220 of them passed away. The development of innovative cancer treatments was made possible by the identification of immune checkpoint inhibitors like CTLA-4 and PD-1/PD-L1 or PD-L2 and programmed cell death-1 protein/programmed death ligand-1 or 2. Many hot tumors (with immunological environments) such as bladder cancer, melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), etc. are reported to respond quite well to checkpoint inhibitors. For patients with various cancer types, including hepatocellular carcinoma (HCC), pancreatic, and prostate cancer, numerous clinical trials have been started to assess the safety and efficacy of immune checkpoint inhibitors.
One of the main oncological issues in Poland is lung cancer. Patients with advanced non-small cell lung cancer (NSCLC) with the expression of PD-L1 may be treated as a first-line option with pembrolizumab monotherapy. Pembrolizumab was given to the patient after stereotactic radiation for central nervous system (CNS) metastases, despite the fact that the disease was already far advanced. The disease was put into partial remission, which was followed by long-term stabilization. Unfortunately, the therapy was stopped after 3 years of treatment due to grade 3 pulmonary toxicity. Despite stopping the pembrolizumab therapy, the condition has stabilized and the inflammatory alterations have gradually subsided with corticosteroid administration.
Market Dynamics
Market Growth Drivers
With the frequency of the disease rising quickly over the past several years, cancer is a significant issue in Poland. Effective cancer treatments like immunotherapy are now more necessary than ever before as a result. The recent significant investments made by the Polish government in healthcare have expanded financing for cancer research and development, particularly immunotherapy. To enhance cancer diagnosis and treatment, Poland has been collaborating with international organizations including the European Union and the World Health Organization. This partnership may increase funding for the study and development of cancer immunotherapy. These factors have resulted in the expansion of the Poland cancer immunotherapy market.
Market Restraints
Although Poland has a robust public healthcare system, the availability and cost of cancer immunotherapy therapies may be impacted by the country's reimbursement policies. Despite initiatives to widen access to healthcare in Poland, certain people may still have only limited access to healthcare services or treatments, particularly in more rural or outlying locations thereby limiting the growth of the Poland cancer immunotherapy market.
Competitive Landscape
Key Players
- Pure Biologics (POL)
- Ryvu Therapeutics (POL)
- Molecure (POL)
- Mabion (POL)
- Captor Therapeutics (POL)
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Pfizer
- Eli Lily
- Novartis
- Johnson & Johnson
- Merck
Healthcare Policies and Regulatory Landscape
Poland's healthcare system is now built upon the mandated public health insurance system. Health care providers who have signed contracts to provide health services with one of the 16 divisions of the National Health Fund (NHZ) in every voivodship are required to provide general health insurance recipients (on a mandatory or voluntary basis) with free medical services. Like the states in the United States, a voivodship is a country's main administrative division. There are 16 voivodships in Poland. The NHF is the organization in charge of delivering and funding medical care for persons with insurance within a set budget. NFZ, a public healthcare system that offers coverage to all Polish citizens and authorized foreign immigrants, pays for cancer treatment in Poland. The majority of cancer treatments, like chemotherapy, radiotherapy, and surgery, are covered by the NFZ; nevertheless, patients may incur some out-of-pocket costs, particularly for more complicated or expensive procedures. The NFZ uses a fee-for-service reimbursement approach, where healthcare practitioners are paid for the services they render. Healthcare professionals are obligated to adhere to the pricing schedules established by the NFZ for various medical operations, including cancer treatment.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
Cancer Immunotherapy Segmentation
By Type (Revenue, USD Billion):
- Monoclonal Antibodies
- Cancer Vaccines
- Checkpoint Inhibitors
- Immunomodulators
- PD-1/PD-L1
- CTLA-4
By Application (Revenue, USD Billion):
- Lung Cancer
- Breast Cancer
- Head and Neck Cancer
- Prostate Cancer
- Colorectal Cancer
- Melanoma
- Others
By End User (Revenue, USD Billion):
- Hospitals
- Clinics
- Ambulatory Surgical Centers (ASCs)
- Cancer Research Centers
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
- Analyzing historical proprietary data collected from multiple projects.
- Regularly updating our existing data sets with new findings and trends.
- Ensuring data consistency and accuracy through rigorous validation processes.
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
- Searching through academic conferences, published research, citations, and social media platforms
- Collecting and compiling diverse data to build a comprehensive and detailed database
- Continuously updating our database with new information to ensure its relevance and accuracy
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
- Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
- Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
- Continuously refreshing our database to ensure that the information remains current and reliable.
- Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
- Merging historical data from secondary research with real-time data from primary research.
- Conducting thorough data validation and cleansing to remove inconsistencies and errors.
- Organizing data into a structured format that is easily accessible and usable for various applications.
- Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
To request a free sample copy of this report, please complete the form below.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
Mabion, Captor Therapeutics, and Bristol-Myers Squibb are the major players in the Poland cancer immunotherapy market.
The Poland cancer immunotherapy market is expected to grow from $653 Mn in 2022 to $1,168 Mn in 2030 with a CAGR of 7.5% for the forecasted year 2022-2030.
The Poland cancer immunotherapy market is segmented by type, application, and end user.
Related reports (by category)
UAE Lymphoma Therapeutics Market Analysis
France Oncology Biosimilars Market Analysis
Malaysia Sleep Disorders Market Analysis
Related reports (by geography)
Poland Diabetes Therapeutics Market Analysis
Poland Lung Cancer Drugs Market Analysis
Poland Oncology Clinical Trials Market Analysis
